A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

Today, The Lancet published the first real-world data analysis of respiratory syncytial virus (RSV) vaccine efficacy among ...

There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...

A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

Connecticut officials said Friday that the state has had two deaths from the flu and 15 to 20 people still die of COVID-19 ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

There has been a surge in cases of a deadly virus with more babies admitted to hospital, according to the UK Health Security ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

WellSpan Ephrata Community Hospital is now offering respiratory syncytial virus immunizations to infants born at the hospital ...

FDA's approval of Astellas' therapy for gastric cancer, and CVS Health's leadership shuffle as Karen Lynch steps down amid ...